These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26729948)

  • 1. Psychiatric aspects of phosphodiesterases: An overview.
    Murthy VS; Mangot AG
    Indian J Pharmacol; 2015; 47(6):594-9. PubMed ID: 26729948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
    Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
    Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.
    Al-Nema MY; Gaurav A
    Curr Top Med Chem; 2020; 20(26):2404-2421. PubMed ID: 32533817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.
    Wang ZZ; Zhang Y; Zhang HT; Li YF
    Curr Pharm Des; 2015; 21(3):303-16. PubMed ID: 25159069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of phosphodiesterases in schizophrenia : therapeutic implications.
    Siuciak JA
    CNS Drugs; 2008; 22(12):983-93. PubMed ID: 18998737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medications for Alzheimer's disease. Benefits of currently approved drugs are limited, but research continues.
    Harv Ment Health Lett; 2011 Apr; 27(10):4-5. PubMed ID: 21786469
    [No Abstract]   [Full Text] [Related]  

  • 7. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
    Zhang HT
    IDrugs; 2010 Mar; 13(3):166-8. PubMed ID: 20191432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase genes and antidepressant treatment response: a review.
    Esposito K; Reierson GW; Luo HR; Wu GS; Licinio J; Wong ML
    Ann Med; 2009; 41(3):177-85. PubMed ID: 18932104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective PDE inhibitors as novel treatments for respiratory diseases.
    Page CP; Spina D
    Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs for psychiatric disorders.
    Med Lett Drugs Ther; 1976 Oct; 18(22):89-96. PubMed ID: 10519
    [No Abstract]   [Full Text] [Related]  

  • 12. The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.
    Rundfeldt C; Socała K; Wlaź P
    J Neural Transm (Vienna); 2010 Nov; 117(11):1319-25. PubMed ID: 20967473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?
    Halene TB; Siegel SJ
    Drug Discov Today; 2007 Oct; 12(19-20):870-8. PubMed ID: 17933689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
    Chappie T; Humphrey J; Menniti F; Schmidt C
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDE inhibition and cognition enhancement.
    Blokland A; Menniti FS; Prickaerts J
    Expert Opin Ther Pat; 2012 Apr; 22(4):349-54. PubMed ID: 22475506
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of phosphodiesterases in neurological and psychiatric disease.
    Hebb AL; Robertson HA
    Curr Opin Pharmacol; 2007 Feb; 7(1):86-92. PubMed ID: 17113826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Psychotropic drugs].
    Müller-Spahn F
    Ther Umsch; 1999 Dec; 56(12):719-25. PubMed ID: 10638279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase inhibitors for cognitive enhancement.
    Rose GM; Hopper A; De Vivo M; Tehim A
    Curr Pharm Des; 2005; 11(26):3329-34. PubMed ID: 16250839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Status of and perspectives on psychiatric genomic medicine].
    Mors NP; Børglum AD
    Ugeskr Laeger; 2005 May; 167(20):2191-3. PubMed ID: 15987082
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphodiesterase inhibitors as potential cognition enhancing agents.
    Schmidt CJ
    Curr Top Med Chem; 2010; 10(2):222-30. PubMed ID: 20166957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.